IL10 and neoplasm: Therefore, based on data mentioned above published by others and results of our in vitro functional assays with the use of DC/shIL-10R_1/TAg, we postulated that this type of DC-based vaccines applied to MC38-tumor bearing mice will be able to trigger an efficient anti-tumor immune response, despite the presence of IL-10 in TME.